logo-loader
Lexaria Bioscience Corp

Lexaria Bioscience Corp announces beverage license deal with California cannabis company

The company said the five-year definitive agreement will provide its Dehydratech technology to a private California-based cannabis company for use in certain cannabis-based beverages

cannabis oil
Lexaria has multiple patents pending in over 40 countries and already has patents in the US and in Australia for Dehydratech

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), announced Wednesday that it has inked an agreement via subsidary Lexaria CanPharm ULC to provide its Dehydratech technology to a private California-based cannabis company for use in certain cannabis-based beverages, which will be produced and sold in California and Nevada. 

The Kelowna-headquartered company said in a release that financial terms of the agreement will not be disclosed and the definitive agreement is for five years. 

The Dehydratech-enabled beverages are protected under Lexaria's existing US-granted patents and may include any combination of ready-to-drink beverages such as non-alcoholic beers, wines and spirits; cold or hot coffee or teas, sports drinks and more.

READ: Lexaria Bioscience renews CEO Chris Bunka and President John Docherty's contracts

Lexaria's technology, Dehydratech, allows cannabidiol (CBD) and other oils to be dehydrated into an odorless, tasteless powder and mixed with xanthan gum, corn flour and other base ingredients which can then be added to foods, drinks and creams.

"Lexaria is currently experiencing unprecedented demand in several North American markets for use of its technology for beverage applications," noted the company in the release. 

Lexaria has multiple patents pending in over 40 countries and already has patents in the US and in Australia for Dehydratech.

Shares of Lexaria were at C$1.36 on Wednesday. 

Contact Katie Lewis at [email protected]

 

Quick facts: Lexaria Bioscience Corp

Price: $0.89

Market: CSE
Market Cap: $69.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp named herein, including the promotion by the Company of Lexaria Bioscience Corp in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Lexaria Bioscience sees positive results from study using DehydraTECH Technology

Lexaria Bioscience (CSE:LXX-OTCQX:LXRP) President John Docherty joined Steve Darling from Proactive Investors Vancouver to talk about a recent controlled, double-blinded European human clinical study that evaluated TurboCBD, Lexaria’s  DehydraTECH powered, cannabidiol fortified hemp-oil...

on 22/2/19

2 min read